Targeting a diverse spectrum of cancers.
Kinase switch control inhibitors for tumor-targeted and immune-targeted cancer therapies.
Deciphera’s proprietary switch control platform has generated a diverse clinical pipeline of kinase inhibitor drug candidates including tumor-targeted therapies and immuno-targeted therapies.
06/18/18 2:23 PM EDT
© Nasdaq. Minimum 15 minutes delayed.
Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities 2018 Life Sciences Conference Read More »
Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock Read More »
Deciphera Pharmaceuticals Announces Pricing of Public Offering Read More »